Antisense Pharma is a biopharmaceutical company committed to research and development of innovative medicines. Our drugs enable targeted treatment of aggressive tumor diseases. Our main objective is to extend the life expectancy of patients considerably and, at the same time, to improve their quality of life.
Founded in 1998, the company is located at the BioPark in Regensburg and in Munich – two of the most successful biotechnology locations in Germany. Our executive management has extensive entrepreneurial experience combined with long-standing proven medical, scientific, and business expertise in biopharmaceuticals. It is supported by a dedicated team with broad experience in the development, approval and commercialization of new medicines.
Our antisense compounds belong to the ‘targeted therapies’, i.e. they block the synthesis of key proteins, which are responsible for the onset and progression of especially aggressive tumor diseases. The drugs do not alter the genome. With this novel approach, we treat the cause of the disease and not merely its symptoms.
Trabedersen, our proprietary drug candidate, is the most advanced in our clinical development. We focus trabedersen’s development on the systemic, intravenous mode of administration in oncological diseases characterized by a high unmet medical need.
Antisense Pharma is an international leader in the development of TGF-β antisense drugs.